Esperion Therapeutics, Inc. (NASDAQ:ESPR)’s share price hit a new 52-week high on Tuesday after Jefferies Group upgraded the stock from a hold rating to a buy rating. Jefferies Group now has a $55.00 price target on the stock. Esperion Therapeutics traded as high as $56.44 and last traded at $56.81, with a volume of 2,826,725 shares changing hands. The stock had previously closed at $45.17.

Other equities analysts have also recently issued research reports about the company. BidaskClub cut Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 4th. UBS AG restated a “buy” rating and issued a $57.00 price objective (up previously from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Stifel Nicolaus restated a “buy” rating and issued a $60.00 price objective (up previously from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. Deutsche Bank AG initiated coverage on Esperion Therapeutics in a report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price objective for the company. Finally, Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $40.39.

A number of large investors have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new stake in shares of Esperion Therapeutics during the first quarter valued at about $158,000. C WorldWide Group Holding A S purchased a new stake in shares of Esperion Therapeutics during the first quarter valued at about $162,000. Princeton Alpha Management LP purchased a new stake in shares of Esperion Therapeutics during the first quarter valued at about $205,000. Bank of Montreal Can increased its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the period. Finally, Aperio Group LLC purchased a new stake in shares of Esperion Therapeutics during the second quarter valued at about $249,000. Institutional investors and hedge funds own 85.20% of the company’s stock.

The stock’s 50 day moving average is $44.47 and its 200 day moving average is $33.65. The stock’s market capitalization is $1.14 billion.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25. During the same period last year, the company earned ($0.62) EPS. Analysts predict that Esperion Therapeutics, Inc. will post ($7.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sets New 1-Year High on Analyst Upgrade” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/10/esperion-therapeutics-inc-nasdaqespr-sets-new-1-year-high-on-analyst-upgrade.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.